Company intelligence / Profile preview
LaNova Medicines
Shanghai, Shanghai, Chinalanovamedicines.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
LaNova has advanced multiple innovative biologic therapies into clinical development, including monoclonal antibodies, ADCs, and bispecifics targeting the tumor microenvironment. Lead assets include LM‑302 (Claudin18.2-targeting ADC in Phase III for gastric cancer) and LM‑299 (PD‑1/VEGF bispecific licensed globally to Merck). The company has secured numerous IND approvals and conducts trials in China, the US, and Australia. Recent results include initiation of a Phase I trial for LM‑299.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Bispecific antibodies (BsAbs)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Merck — exclusive global license for anti-PD–1/VEGF bispecific antibody LM–299 ($588M upfront + milestones up to $2.7B)Previously had a partnership with Bristol Myers Squibb on Claudin18.2-targeting ADC but this was terminated in late 2024.
Beyond the preview
Go deeper on LaNova Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LaNova Medicines.